A 16 week open-label outpatient, randomized, parallel study assessing the impact of two different initial dose prescriptions for dry powder inhaled insulin (Exubera) on glycemic control in patients with type 2 diabetes mellitus who are poorly controlled on a combination of two or more oral agents.
Phase of Trial: Phase IV
Latest Information Update: 21 May 2008
At a glance
- Drugs Insulin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Sponsors Pfizer
- 31 Aug 2018 Biomarkers information updated
- 21 May 2008 Status changed from recruiting to discontinued (because Pfizer decided to return the worldwide rights for Exubera to Nektar, on 18 October 2007).
- 18 Oct 2007 Trial centre added.